Suitability of Metipranolol for Glaucoma Therapy from the Pharmacological Viewpoint

Pharmacological Properties of Metipranolol in Glaucoma Therapy
  • E. A. Noack
Conference paper


In the title of this report I mention the suitability of Metipranolol. What I mean is the usefulness of this beta-receptor blocking agent in topical administration to the eye, judged on the basis of its pharmacological properties but not with reference to efficacy from the clinical viewpoint. Beta-receptor blocking agents have now been used successfully for 15 years in glaucoma and to my understanding there cannot be any doubt about the basis efficacy of all beta-blocking agents which are on the market for this form of therapy.


Intraocular Pressure Adrenergic Receptor Topical Application Blocking Agent Ciliary Epithelium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Phillips, C. I., Howitt, G., Rowlands, D. J.: Propranolol as ocular hypotensive agent. Brit. J. Ophthalmol. 51, 222–226 (1967).CrossRefGoogle Scholar
  2. 2.
    Wettrell, K., Pandolfi, M.: Propranolol vs. acetazolamide. A long-term double masked study of the effect on intraocular pressure and blood pressure. Arch. Ophthalmol. 97, 280–283 (1979).PubMedCrossRefGoogle Scholar
  3. 3.
    McDonald, M., et al.: Comparison of ocular hypotensive effects of acetazolamide and atenolol. Br. J. Ophthalmol. 61,345–348 (1977).Google Scholar
  4. 4.
    Elliot, M. H., Cullen, P. M., Philipps, C. I.: Ocular hypotensive effect of atenolol — tenormin I. C. I. — a new beta-adrenergic blocker. Br. J. Ophthalmol. 59, 296 (1975).Google Scholar
  5. 5.
    Bucci, M. G., Missiroli, A., Giraldi, J.: Local administration of propranolol in the treatment of glaucoma. Boll. Oculist. 47, 51–60 (1968).PubMedGoogle Scholar
  6. 6.
    Ros, F. E., Dake, C. L., Nagelkerke, N. J. D., Greve, E. L.: Metoprolol eye drops in the treatment of glaucoma. A double-blind single dose trial of a betas-adrenergic blocking drug. Graefes Arch. Klin. Exp. Ophthalmol. 206, 247–254 (1978).Google Scholar
  7. 7.
    Bonomi, L., Perfetti, S., Noya, E., Bellucci, R., Massa, F.: Comparison of the effect of nine beta-adrenergic blocking agents on intraocular pressure in rabbits. Graefes Arch. Klin. Exp. Ophthalmol. 210, 1–8 (1979).Google Scholar
  8. 8.
    Katz, I. M.: Beta-blockers and the eye. An overview. Ann. Ophthalmol. 10, 847–850 (1978).PubMedGoogle Scholar
  9. 9.
    Leydhecker, W.: Sympathikomimetika and Sympathikolytika in der Glaukomtherapie. Klin. Mbl. Augenheilk. 171, 538–546 (1977).Google Scholar
  10. 10.
    Nielsen, N. V.: Timolol und Metoprolol. Okulärer hypotensiver Effekt, lokale und systemische Begleiteffekte. Z. prakt. Augenheilk. 2, 71–77 (1981).Google Scholar
  11. 11.
    Krieglstein, G. K., Leydhecker, W.: Medikamentöse Glaukomtherapie. München: Bergmann. 1982.CrossRefGoogle Scholar
  12. 12.
    Kern, R.: Zur Verteilung der adrenergen Rezeptoren im M. sphincter pupillae, im M. dilatator pupillae und im Ziliarkörper des Menschen; deren Bedeutung bei der Behandlung der Hypotonia bulbi und des Glaukoms. In: Medikamentöse Glaukomtherapie (Krieglstein, G. K., Leydhecker, W., eds.), pp. 133 ff. München: Bergmann. 1982.Google Scholar
  13. 13.
    Sears, M. L., Barany, E. H.: Outflow resistance and adrenergic mechanisms. Effects of sympathectomy, N-(2-chloroethyl)dibenzylamine hydrochloride (dibenamine), and dichloroisoproterenol on the outflow resistance of the rabbit eye. Arch. Ophthalmol. 64, 839–848 (1960).PubMedCrossRefGoogle Scholar
  14. 14.
    Takase, M.: Effects of propranolol on aqueous dynamics in primary openangle glaucoma. Acta Soc. Ophthalmol. Jpn. 80, 310–314 (1976).Google Scholar
  15. 15.
    Potter, D. E.: Adrenergic pharmacology of aqueous humor dynamics. Pharmacol. Review 33, 133–153 (1981).Google Scholar
  16. 16.
    Vareilles, P., Lotti, V. J.: Effect of timolol on aqueous humor dynamics in the rabbit. Ophthalmic Res. 13, 72–79 (1981).CrossRefGoogle Scholar
  17. 17.
    Cruickshank, J. M.: The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am. Heart J. 100, 160–178 (1980).PubMedCrossRefGoogle Scholar
  18. 18.
    Takats, I., Szilvassy, I., Kerek, A.: Intraocularer Druck und Kammerwasserzirkulationsuntersuchungen an Kaninchenaugen nach intravenöser Verabreichung von Propranolol (Inderal). Graefes Arch. Klin. Exp. Ophthalmol. 185, 331–342 (1972).Google Scholar
  19. 19.
    Öhrström, A., Kättström, O.: Interaction of timolol and adrenaline. Br. J. Ophthalmol. 65, 53–55 (1981).PubMedCrossRefGoogle Scholar
  20. 20.
    Innemee, H. C., De Jonge, A., Van Meel, J. C. A., Timmermanns, P. B. M., Von Zwieten, P. A.: The effect of selective al-and a2-adrenoceptor stimulation on intraocular pressure in the conscious rabbit. Naunyn-Schmiedebergs Arch. Pharmacol. 316, 294–298 (1981).Google Scholar
  21. 21.
    Neufeld, A. H., Page, E. D.: In vitro determination of the ability of drugs to bind to adrenergic receptors. Invest. Ophthalmol. Visual Sci. 16, 1118–1124 (1977).Google Scholar
  22. 22.
    Mittag, T., Tormay, A.: Adrenergic receptors in iris-ciliary body: direct ligand binding studies. Invest. Ophthalmol. Visual Sci. (A. R. V. O. suppl.) 20, 198 (1981).Google Scholar
  23. 23.
    Dafna, Z., Lahav, M., Melamad, E.: Localization of beta-adrenoceptors in the anterior segment of the albino rabbit eye using a fluorescent analog of propranolol. Exp. Eye Res. 29, 327–330 (1979).PubMedCrossRefGoogle Scholar
  24. 24.
    Bromberg, B. B., Gregory, D. S., Sears, M. L.: Beta-adrenergic receptors in ciliary processes of the rabbit. Invest. Ophthalmol. Visual Sci. 19, 203–207 (1980).Google Scholar
  25. 25.
    Nathanson, J. A.: Effects of a potent and specific ß2-adrenoceptor antagonist on intraocular pressure. Br. J. Pharmacol. 73, 91–100 (1981).CrossRefGoogle Scholar
  26. 26.
    Thomas, J. V.: Ocular adrenergic receptor sites pertinent to aqueous humor dynamics. Ann. Ophthalmol. 12, 96–98 (1980).Google Scholar
  27. 27.
    Pentikäinen, P. J., Neuvonen, P. J., Penttila, A.: Assessment of beta-blocking activity of trimepranol in man. Int. J. Clin. Pharmacol. 6, 279–284 (1978).Google Scholar
  28. 28.
    Zakhari, S., Pronay, N., Drimal, J., Molnar, L.: Correlations between the partition coefficient and the beta-adrenolytic activities of trimepranol and its analogues. Bratislayské lékalske Listy 62, 678–688 (1974).Google Scholar
  29. 29.
    Bieth, N., Rouot, B., Schwartz, J., Velly, J.: Comparison of pharmacological and binding assays for ten ß-adrenoceptor blocking agents and two ß-adrenoceptor agonists. Br. J. Pharmacol. 68, 563–569 (1980).PubMedCrossRefGoogle Scholar
  30. 30.
    Dreyer, A. C., Offermeier, J.: In vitro assessment of the selectivities of various beta-adrenergic blocking agents. Life Sci. 27, 2087–2098 (1980).PubMedCrossRefGoogle Scholar
  31. 31.
    Kaumann, A. J., Mclnerny, T. K., Gilmour, D. P., Blinks, J. R.: Comparative assessment of ß-adrenoceptor blocking agents as simple competitive agonists in isolated heart muscle. Naunyn-Schmiedebergs Arch. Pharmacol. 311, 219–236 (1980).Google Scholar
  32. 32.
    Noack, E.: Untersuchungen zur spezifischen adrenolytischen and unspezifisch kardiodepressiven Wirkung des ß-Rezeptorenblockers Acebutolol. Arzneim.-Forsch./Drug Res. 31, 1410–1416 (1981).Google Scholar
  33. 33.
    Colasanti, B. K., Trotter, R. R.: Effects of selective beta,- and beta2adrenoceptor agonists and antagonists on intraocular pressure in the cat. Invest. Ophthalmol. Visual Sci. 20, 69–76 (1981).Google Scholar
  34. 34.
    Demmler, N.: Beta-Rezeptorenblocker in der Ophthalmologie. Med. Mo. Pharm. 3, 174–179 (1980).Google Scholar
  35. 35.
    Bartsch, W., Sponer, G., Dietmann, K.: Experiments in animals on the pharmacological effects of metipranolol in comparison with prop ranolol and pindolol. Arzneim.-Forsch./Drug Res. 27, 2319–2322 (1977).Google Scholar
  36. 36.
    Trcka, V.: Pharmacological activtities of trimepranol and its fate in the organism, Part 2. Res. Institute for Pharmacy and Biochem., Prague 1973.Google Scholar
  37. 37.
    Hopf, R., Tourbier, H., Kaltenbach, M.: Wirksamkeit des Beta-Sympathikolytikums Methypranolol auf Belastungsherzfrequenz and ischämische ST-Senkung im Vergleich mit Plazebo and Propranolol. Herz/ Kreislauf 9, 560–565 (1977).Google Scholar
  38. 38.
    Cocan, D. G., Hirsch, E. D.: The cornea, VII. Permeability to weak electrolytes. Arch. Pharmacol. 32, 276–282 (1944).Google Scholar
  39. 39.
    Swan, K. C., White, N. G.: Corneal permeability, I. Sectors effecting penetration of drugs into the cornea. Am. J. Ophthalmol. 25, 1043–1058 (1942).Google Scholar
  40. 40.
    Schmitt, C. J., Lotti, V. J., Le Duarce, J. C.: Penetration of timolol into the rabbit eye. Measurement after ocular installation and intravenous injection. Arch. Ophthalmol. 98, 547–551 (1980).PubMedCrossRefGoogle Scholar
  41. 41.
    Ross, F. E., Innemee, H. C., Van Zwieten, P. A.: Penetration of atenolol in the rabbit eye. Graefes Arch. Klin. Exp. Ophthalmol. 208, 235–240 (1978).Google Scholar
  42. Hellenbrecht, D., Lemmer, B., Wiethold, G., et al.: Measurement of hydrophobicity, surface activity, local anaesthesis and myocardial conduction velocity as quantitative parameters of the non-specific membrane affinity of nine 4-adrenergic blocking agents. NaunynSchmiedebergs Arch. Pharmacol. 277,211–226 (1973).Google Scholar

Copyright information

© Springer-Verlag Wien 1984

Authors and Affiliations

  • E. A. Noack
    • 1
  1. 1.Institut für PharmakologieUniversität DüsseldorfDüsseldorf 1Federal Republic of Germany

Personalised recommendations